A. I. Gimazova

A. I. Gimazova

Auto-generated profile, based on publicly available information

A. I. Gimazova

State Novosibirsk Regional Clinical Hospital

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2023 in Creative surgery and oncology
Verified
Journal Article
Open access
PDF file
AAA. M. Avzaletdinov
A. M. Avzaletdinov
VPValentin Nikolaevich Pavlov
Valentin Nikolaevich Pavlov
ТВТ. Д. Вильданов
Т. Д. Вильданов
AGA. I. Gimazova
A. I. Gimazova
NZN. A. Zdorik
N. A. Zdorik
KMK. R. Musakaeva
K. R. Musakaeva
Introduction. Esophageal pathology constitutes a small share in general morbidity, however, it remains highly relevant due to its social and clinical significance. Corrosive strictures account for a large proportion among benign esophageal diseases. Treatment of the disease starts with intraluminal surgery. However, it provides only short-term effect due to the tendency of esophageal strictures to restenosis. In case of treatment failure, esophagoplasty is performed. The esophagoplasty according to Ivor Lewis with the formation of manual intrapleural anastomosis was performed in the BSMU Clinic. The abdominal and thoracic phases were performed using Da Vinci Si robotic surgical system. By the time of publication of this paper, the authors have gained experience of 15 successfully performed surgeries of this kind.Materials and methods. The paper presents a clinical case of robot-assisted esophagoplasty according to Ivor Lewis performed on patient Y., born in 1978, with the clinical diagnosis: corrosive strictures of the lower third of the esophagus with dysphagia of III–IV degree. The pathology developed as a result of surrogate alcohol consumption in September 2017. Since October 2017, the patient has been regularly treated in the Thoracic Surgery Unit of the BSMU Clinic, where she underwent a number of endoscopic surgeries, which appeared to provide a little effect. The patient underwent a subsequent surgical treatment including esophagoplasty according to Ivor Lewis with the formation of manual intrapleural anastomosis using Da Vinci Si robotic system.Results and discussion. First three days of the postoperative period, the patient remained in the Anaesthesiology and Intensive Care Unit. She received step-by-step parenteral and enteral nutrition. Control fl uoroscopic examinations revealed timely, disturbances-free evacuation and no contrast leakage from the formed anastomosis. The patient was discharged on day 11 in satisfactory condition.Conclusion. Using Da Vinci robot-assisted system in Lewis esophageal plastic surgery has a number of specific features. It provides more precise tissue extraction with preservation of stomach and esophageal vessels, moreover, mobility of the instruments enables the key phase to be performed, namely — manual suturing in the esophagoanastomosis. As a result, the risk of postoperative complications is reduced.

6 December 2023 in Creative surgery and oncology
Verified
Journal Article
Open access
PDF file
GKGulnaz Faritovna Korytina
Gulnaz Faritovna Korytina
IGI. A. Gibadullin
I. A. Gibadullin
SZShamil Zulkarneev
Shamil Zulkarneev
AGA. I. Gimazovа
A. I. Gimazovа
VMVitaliy Markelov
Vitaliy Markelov
NZNaufal Zagidullin
Naufal Zagidullin
Introduction. Idiopathic pulmonary fibrosis (IPF) comprises an interstitial lung disease with unclear pathogenesis, rapid progression, and no effective treatment. Pulmonary fibrosis is reported to be one of the most severe complications induced by a new coronavirus infection COVID-19. The mechanisms triggering pulmonary fibrosis and leading to its rapid progression remain substantially unclear. Evidence suggests that immune and genetic factors contribute to the development of this disease. Among the latter, the role of long non-coding RNAs (dnRNAs) has been actively studied to date. Materials and methods. Considering the role of TP53TG1, LINC00342, H19, MALAT1, DNM3OS, and MEG3 dnRNAs as regulators of signaling pathways associated with fibroblast activation and epithelial-mesenchymal transition, the authors analyzed the expression level of selected dnRNAs in lung tissue and blood mononuclear cells of patients with IPF (N = 12), post-COVID-19 pulmonary fibrosis (N = 14), and in control group (N = 27). Results and discussion. Blood mononuclear cells in patients with IPF and post-COVID-19 PF revealed similar patterns of TP53TG1 and MALAT1 dnRNA expression. The level of relative expression of MALAT1 was significantly higher in patients with IPF (Fold Change=3.207, P = 0.0005) and with post-COVID-19 PF (Fold Change=9.854, P = 0.0003), while the relative expression level of TP53TG1 reduced in patients with IPF (Fold Change=0.4308, P = 0.0313) and with post-COVID-19 PF (Fold Change=0.1888, P = 0.0003 in blood mononuclear cells, Fold Change=0.1791, P = 0.0237 in lung tissue). Increased expression of DNM3OS in blood mononuclear cells (Fold Change=12.899, P = 0.0016) and lung tissue (Fold Change=9.527, P = 0.0001), LINC00342 (Fold Change=2.221, P = 0.0309) in blood mononuclear cells was revealed only in patients with IPF. Conclusion. Evaluation of the dnRNA expression profile of TP53TG1, LINC00342, MALAT1 and DNM3OS in blood mononuclei can be used as an informative and non-invasive biomarker in IPF and post COVID-19 PF.

30 December 2023 in Yakut Medical Journal
Verified
Journal Article
Closed access
RZR.KH. Zulkarneev
R.KH. Zulkarneev
SZShamil Zulkarneev
Shamil Zulkarneev
GKGulnaz Faritovna Korytina
Gulnaz Faritovna Korytina
IGI.A. Gibadullin
I.A. Gibadullin
AAA.M. Avzaletdinov
A.M. Avzaletdinov
NZNaufal Zagidullin
Naufal Zagidullin
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease of unknown origin with an average life expectancy of 3-5 years after diagnosis. The disease is accompanied by progressive pulmonary fibrosis, decreased lung function, poor response to therapy and early mortality. Various biomarkers, including serum biomarkers, are used for timely and differential diagnosis of idiopathic pulmonary fibrosis (IPF) and COVID-19-associated pulmonary fibrosis (PF), predicting the course of the disease and assessing the effectiveness of specific therapy. Target was to investigate the features of pulmonary fibrosis based on serum biomarkers in patients with ILF and COVID-19-associated fibrosis. Methods. Changes in serum concentrations of biomarkers CA15-3, LOXL2, TGFBR3 and periostin in patients with ILF (n=10), COVID-19-associated pulmonary fibrosis and controls were investigated. Results. Significant differences were found between LOXL2 concentrations in the control and ILF groups (p=0.003), ILF and COVID-19-associated fibrosis groups (p=0.036) and between periostin concentrations in the control and ILF groups (p=0.042). ROC analysis for LOXL2 revealed: in the ILF and control groups AUC=0.854 (95% CI 0.693-1.0; p<0.0001), with a sensitivity of 80.0% and specificity of 76.9%; in the ILF and COVID-19-associated LF groups AUC=0.773 (95% CI 0.556-0.989; p=0.014) with a sensitivity of 99.0% and specificity of 63.6%. For periostin: AUC=0.692 (95% CI 0.469-0.916; p=0.092) with a sensitivity of 50.0% and specificity of 84.6%. Correlation analysis in the pooled group showed a significant correlation for CA15-3 and periostin (rs=0.383; 95% CI 0.042-0.645; p=0.025), LOXL2 and periostin (rs=0.509; 95% CI 0.196-0.727; p=0.002), TGFBR3 and CA15-3 (rs=0.347; 95% CI 0.0-0.62; p=0.044). Conclusions. We found significant differences between serum levels of LOXL2 in ILF group and CG, ILF group and COVID-19-associated LF. ROC analysis yielded the values of the optimal points of group separation by serum LOXL2 and periostin levels. This allows differential diagnosis of different pulmonary fibrosis. Keywords: pulmonary fibrosis, IPF, COVID-19, CA15-3, periostin, TGFBR3, LOXL2.